Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $846.50 million. The enterprise value is $860.37 million.
Important Dates
The next confirmed earnings date is Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 93.74 million shares outstanding. The number of shares has increased by 44.36% in one year.
| Current Share Class | 93.74M |
| Shares Outstanding | 93.74M |
| Shares Change (YoY) | +44.36% |
| Shares Change (QoQ) | +18.64% |
| Owned by Insiders (%) | 6.75% |
| Owned by Institutions (%) | 2.01% |
| Float | 23.41M |
Valuation Ratios
The trailing PE ratio is 197.18.
| PE Ratio | 197.18 |
| Forward PE | n/a |
| PS Ratio | 7.63 |
| Forward PS | 15.26 |
| PB Ratio | 12.92 |
| P/TBV Ratio | 14.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 118.66 |
| EV / Sales | 8.55 |
| EV / EBITDA | 71.75 |
| EV / EBIT | 82.48 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.60 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 12.12% and return on invested capital (ROIC) is 6.69%.
| Return on Equity (ROE) | 12.12% |
| Return on Assets (ROA) | 5.18% |
| Return on Invested Capital (ROIC) | 6.69% |
| Return on Capital Employed (ROCE) | 9.41% |
| Revenue Per Employee | $173,822 |
| Profits Per Employee | $12,523 |
| Employee Count | 579 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.59 |
Taxes
In the past 12 months, GYRE has paid $3.68 million in taxes.
| Income Tax | 3.68M |
| Effective Tax Rate | 23.91% |
Stock Price Statistics
The stock price has decreased by -36.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.03% |
| 50-Day Moving Average | 9.29 |
| 200-Day Moving Average | 11.63 |
| Relative Strength Index (RSI) | 55.23 |
| Average Volume (20 Days) | 107,980 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GYRE had revenue of $100.64 million and earned $7.25 million in profits. Earnings per share was $0.04.
| Revenue | 100.64M |
| Gross Profit | 96.84M |
| Operating Income | 10.43M |
| Pretax Income | -74.61M |
| Net Income | 7.25M |
| EBITDA | 11.99M |
| EBIT | 10.43M |
| Earnings Per Share (EPS) | $0.04 |
Full Income StatementBalance Sheet
The company has $29.89 million in cash and $1.59 million in debt, giving a net cash position of $28.31 million or $0.30 per share.
| Cash & Cash Equivalents | 29.89M |
| Total Debt | 1.59M |
| Net Cash | 28.31M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 104.30M |
| Book Value Per Share | 0.79 |
| Working Capital | 49.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 96.23%, with operating and profit margins of 10.36% and 7.20%.
| Gross Margin | 96.23% |
| Operating Margin | 10.36% |
| Pretax Margin | 15.27% |
| Profit Margin | 7.20% |
| EBITDA Margin | 11.91% |
| EBIT Margin | 10.36% |
| FCF Margin | n/a |